Group 1: Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 106,042.91 million yuan, a year-on-year increase of 8.53% [1] - The net profit attributable to shareholders of the parent company reached 16,672.64 million yuan, growing by 15.85% [1] - The third quarter of 2024 saw operating revenue of 38,417.83 million yuan, up 18.16% year-on-year, with a net profit of 6,067.28 million yuan, increasing by 17.04% [1] - The net profit after deducting non-recurring gains and losses was 5,898.46 million yuan, reflecting a year-on-year growth of 21.18% [1] Group 2: Market Expansion and Strategy - The company is constructing a factory in Mexico to meet the growing capacity demands of overseas clients and to enhance its global layout strategy [2] - The Mexican factory will be built in two phases, with the first phase focusing on automated production lines for North and South American clients, expected to be operational by early 2026 [2] - The establishment of the factory is anticipated to significantly improve the company's overseas product supply and customer service capabilities, enhancing its competitiveness and risk resilience [2] Group 3: Customer and Market Response - Overseas clients have shown strong support for the company's factory in Mexico, viewing it as beneficial for reducing transportation and storage costs while improving procurement and communication efficiency [2] - The company has implemented robust foreign exchange management practices, minimizing the impact of currency fluctuations on overall performance [2] Group 4: Future Development Strategy - The company will continue to focus on the medical catheter field while expanding into active medical devices through independent and collaborative R&D [3] - Recent acquisitions have enriched the product matrix in anesthesia and urology, aiming to enhance revenue through product synergy [3] - The strategic goal is to become a global leader in the research and manufacturing of medical catheters and related products [3]
维力医疗(603309) - 维力医疗投资者关系活动记录表(20241108)